Brief: Theranexus Aims To Start Pivotal Phase III Trials For Batten Disease At End Of 2022

Thx Pharma SA

28/02/2022 06:43

Feb 28 (Reuters) - Theranexus SA  ALTHX.PA :
    * START OF PHASE I/II CLINICAL TRIAL FOR BATTEN DISEASE
    * NEW MILESTONE FOR NEUROLEAD, THE ACTIVE AGENT SCREENING
PLATFORM
    * INITIAL RESULTS OF TITRATION PHASE WILL BE AVAILABLE AT
START OF
SECOND HALF OF 2022
    * AFTER CONSULTING WITH FDA, AT END OF 2022 THERANEXUS AIMS
TO
START PIVOTAL PHASE III TRIALS
    * IN FEBRUARY 2022 THERANEXUS RECEIVED A PAYMENT OF EUR1.7
MILLION
FROM BPIFRANCE THROUGH INVESTMENTS FOR FUTURE PROGRAM (PIA)
    * IN ADDITION TO THIS SUM, FUNDING OF EUR800,000 WAS ALSO
PROVIDED
BY A BPIFRANCE RESEARCH AND DEVELOPMENT INNOVATION LOAN TO SPEED
UP DEVELOPMENT OF PLATFORM

Source text for Eikon:  ID:nACT73371 
Further company coverage:  ALTHX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))